Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host disease in patients unde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Itacitinib (itacitinib)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING